Welcome to our dedicated page for Metagenomi Therapeutics SEC filings (Ticker: MGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Metagenomi Therapeutics, Inc. (Nasdaq: MGX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public biotechnology issuer focused on in vivo genome editing and precision genetic medicines. These filings offer detailed information on financial performance, pipeline progress, and key corporate events related to its proprietary gene editing toolbox and programs such as MGX-001 for hemophilia A.
Metagenomi, Inc. files current reports on Form 8-K to announce material events, including quarterly financial results, business updates, and new preclinical data. For example, Form 8-K filings reference press releases that discuss non-human primate data for MGX-001, strategic pipeline prioritization, and corporate presentations. These 8-Ks often furnish exhibits containing full press releases and investor slide decks, which can provide additional scientific and strategic context.
Investors can also review quarterly reports on Form 10-Q and other periodic filings, which the company notes in its press releases, for more comprehensive discussions of research and development activities, collaboration revenue, operating expenses, and risk factors. As an emerging growth company, Metagenomi discloses its status and related accounting elections within these documents.
On Stock Titan, MGX filings are updated from the SEC’s EDGAR system, and AI-powered tools can help summarize lengthy documents such as 10-Qs and 10-Ks, highlight key sections, and clarify technical language. Users can quickly identify items related to in vivo genome editing programs, collaboration agreements, capital allocation, and organizational changes. In addition, Form 4 and other insider transaction reports, when filed, can be reviewed to monitor trading activity by directors and officers.
This page is a central resource for analyzing Metagenomi Therapeutics’ official disclosures, from financial results and pipeline data to governance updates, supporting deeper research into the MGX investment and its genome editing platform.
Metagenomi, Inc. has changed its corporate name to Metagenomi Therapeutics, Inc., effective 12:01 a.m. Pacific Time on January 12, 2026, through a certificate of amendment to its charter approved by the board under Delaware law. The change does not affect stockholder rights.
The board also amended and restated the company’s bylaws solely to reflect the new name, with no other changes. The company’s common stock will continue to trade on the Nasdaq Global Select Market under the symbol MGX, and the CUSIP number for the common stock will remain the same. A press release and a January 2026 corporate presentation related to the name change and business updates were furnished as exhibits.
Metagenomi, Inc. (MGX) reported Q3 2025 results. Collaboration revenue was $8.7 million, down from $11.5 million a year ago, while operating expenses declined to $31.5 million from $33.9 million. Net loss was $20.4 million versus $18.8 million last year, or $0.55 per share.
Cash and cash equivalents were $32.8 million and available-for-sale marketable securities were $151.3 million as of September 30, 2025, supporting management’s view that liquidity is sufficient for at least the next 12 months. Deferred revenue totaled $14.8 million, reflecting ongoing recognition under the Ionis collaboration.
The company terminated the Affini‑T agreement following Affini‑T’s assignment for the benefit of creditors and marked its Affini‑T investment to zero. Metagenomi also signed a non‑exclusive LNP license with Acuitas, recording a $3.0 million upfront licensing fee in research and development expense. Under the Ionis agreement, the company recognized $8.5 million of collaboration revenue in Q3 and reported $20.0 million remaining performance obligations to be recognized over future periods. Shares outstanding were 37,546,751 as of September 30, 2025.
Metagenomi, Inc. (MGX) filed an 8‑K announcing it furnished a press release with financial results for the quarter ended September 30, 2025 and additional business updates. The company also furnished a separate press release reporting positive dose range finding data from its MGX-001 hemophilia A program, and made its November 2025 corporate presentation available. These materials are furnished, not filed, under the Exchange Act.
Included exhibits are: 99.1 (earnings press release dated November 11, 2025), 99.2 (MGX-001 program update press release dated November 11, 2025), 99.3 (corporate presentation dated November 2025), and 104 (cover page Inline XBRL).
Metagenomi, Inc. filed a Form 144 notifying a proposed sale of 35,832 common shares through Merrill Lynch on 09/11/2025 on the NASDAQ, with an aggregate market value of $68,080.80. The filing shows the shares were acquired as stock awards from Sarah Noonberg: 26,631 shares on 01/30/2003 and 9,201 shares on 06/05/2025, with payment listed as cash. The issuer has 37,533,136 shares outstanding. The filer reports no sales of the issuer's securities in the past three months and includes the standard signer representation that no undisclosed material adverse information exists.
Metagenomi director Reid Laurence was granted a stock option covering 42,000 shares of common stock with an exercise price of $1.82. The option grant is recorded as an acquisition on 09/02/2025 and is held directly by the reporting person. The disclosed vesting schedule states that 33% of the option shares vest and become exercisable on 09/02/2026, with the remaining shares vesting in 24 equal monthly installments thereafter, subject to continued service. The option underlying shares are described as Common Stock and the reporting form is signed by an attorney-in-fact for the reporting person.
Reid Laurence, identified as a director of Metagenomi, Inc. (MGX), filed an initial Form 3 reporting his beneficial ownership status. The filing states that no securities are beneficially owned by the reporting person. This is a routine Section 16 disclosure indicating the director currently holds no reportable equity or derivative positions in the issuer.
Metagenomi, Inc. reported interim results showing continued R&D spending and collaboration revenue while maintaining a multi-month cash runway. Total assets decreased to $272.3 million from $324.6 million, driven primarily by lower available-for-sale marketable securities of $178.1 million versus $220.9 million at year-end. Cash and cash equivalents were $26.9 million and, together with marketable securities, management states approximately $205.0 million of liquidity is available to fund operations for at least the next 12 months.
Collaboration revenue for the quarter was $8.5 million, primarily from Ionis, while operating expenses totaled $29.5 million for the quarter with R&D at $22.5 million. Net loss was $19.9 million for the quarter and $44.9 million for the six months, widening year-over-year. The company recognized a $1.3 million fair value loss on its long-term investment in Affini-T, which it valued at $0.0 million at June 30, 2025. Deferred revenue related to Ionis remains material at $22.4 million. A securities class action filed in September 2024 is pending and the company filed a motion to dismiss in May 2025.
Metagenomi, Inc. announced its financial results for the quarter ended June 30, 2025 and provided additional business updates. The company furnished a press release and a corporate presentation as Exhibits 99.1 and 99.2 to this Current Report; these exhibits are furnished rather than filed and are not incorporated by reference except as expressly stated in a future filing. The report confirms the company’s common stock trades under the ticker MGX on the Nasdaq Global Select Market and indicates Metagenomi qualifies as an emerging growth company. No financial metrics or operational details are included in the body of this filing.